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conventional radiotherapy techniques. It has been shown that 
the dosimetrical benefit of IMRT translated into a clinically 
significant reduction in lower gastrointestinal toxicity 
compared with three-field conventional radiotherapy. MRI-
linacs and proton therapy are likely to broaden the 
therapeutic window further in the near future. Prone 
positioning on a bellyboard reduces small bowel toxicity by 
pushing away the small bowel loops from the high dose 
region. Image-guided radiotherapy allows for an accurate 
definition, localization and monitoring of tumor position, size 
and shape before and during treatment and may help to 
reduce set-up margins.  
Small randomized controlled trials have shown that the 
administration of several agents might have a beneficial 
effect for the prevention of acute (e.g. intrarectal 
amifostine, oral sulfasalazine and balsalazide) and/or late-
onset radiation-induced toxicity (intrarectal beclomethasone 
and oral probiotics). Once severe toxicity develops, total 
replacement of the diet with elemental formula may be 
appropriate. Probiotics influence the bacterial microflora and 
seem promising in reducing the incidence and severity of 
radiation-induced diarrhea. Currently there is insufficient 
evidence for cytoprotective and anti-inflammatory drugs in 
the management of radiation-induced toxicity. Future 
challenges lie in the prediction of treatment-related toxicity, 
which might be a promising step towards an individualized 
risk-adapted treatment.  
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Glioblastoma (GBM) is the most common and most malignant 
primary brain tumor in adults with a dismal prognosis of 15 to 
18 months and few therapeutic options. GBM are notorious 
for their resistance to therapies, likely due to a plethora of 
genetic and epigenetic alterations affecting multiple cancer 
relevant pathways conferring enhanced adaptive plasticity to 
tumor cells. The addition of concomitant and adjuvant 
temozolomide to radiotherapy has been introduced 10 years 
ago based on the pivotal EORTC-NCIC trial. At the same time, 
the predictive value of promoter methylation of the repair 
gene MGMT for benefit from the alkylating agent 
temozolomide has been established. Despite efforts in 
developing targeted agents this combination therapy is still 
the current the standard of care. Clinical trials have used the 
combination therapy as backbone and added new drugs, 
immunotherapies, or use of devices. Or, in a second strategy, 
patients were selected according to their MGMT status. 
MGMT unmethylated patients who basically do not profit 
from alkylating agent therapy can be entered into trials 
omitting temozolomide. This allows avoiding unnecessary 
toxicity, thereby enhancing chances for new drugs and 
providing new options for patients with a particularly bad 
prognosis. Advances of molecular techniques have led to 
discovery of new genetic and epigenetic alterations with 
prognostic and predictive value that have changed tumor 
classification, in particular in lower grade gliomas. This 
emphasizes the importance of collection of tumor tissue 
within clinical trials to test respective markers that need to 
be taken into account when analyzing completed trials or 
devising new strategies for clinical trials. Druggable 
mutations are usually only present in a relatively small subset 
of patients, a fact that is observed across tumor types. 
Therefore, in a new strategy the EORTC has launched the 
SPECTA program – allowing for efficient biomarker screening 
across all tumor types for improving access to molecularly 
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The growth and development of solid tumours requires an 
adequate supply of oxygen and nutrients. Initially this is 
obtained from the vascular supply of the normal tissue in 
which the tumour arises. However, the demands of the 
growing tumour mass soon exceed the supply from this source 
and further growth is only possible if the tumour forms its 
own blood supply from the host vessels via the process of 
angiogenesis. This significance of the tumour neo-vasculature 
makes it an excellent target and two approaches have now 
emerged. These are the more popular use of drugs that 
inhibit the angiogenesis process and the less popular use of 
agents that disrupt the already established tumour 
vasculature. This latter approach actually has a much longer 
history than angiogenesis inhibitors. Indeed, the first vascular 
disrupting agent (VDA) investigated as an anti-tumour agent 
was colchicine back in the 1930s. Although it was shown to 
possess significant anti-tumour activity in both pre-clinical 
and clinical studies, it was also found to have substantial 
systemic toxicity. Later agents with VDA activity were also 
very toxic. This changed in the 1980s when combretastatin A-
4 phosphate (fosbretabulin) was developed from products 
isolated from the bark of the African Bush Willow and found 
to have anti-tumour activity at doses well below those that 
caused systemic toxicity. Numerous other VDAs have since 
been developed with similar anti-tumour/toxicity profiles 
and many are under clinical evaluation. These include 
fosbretabulin, ombrabulin, crinobulin, and plinabulin. 
Although the vascular damage induced by VDAs can be severe 
and translates into a significant inhibition of tumour growth, 
it is never sufficient to induce tumour control, thus the 
potential of VDAs is not when used alone but when combined 
with conventional radiation or chemotherapy. Drug, timing, 
and sequencing are critical in such combinations. For 
radiation, pre-clinical studies performed using optimum 
conditions have shown a variety of different VDAs to be 
capable of significantly improving tumour response when the 
radiation is administered either as single treatments or in 
more clinically relevant fractionated and stereotactic 
schedules. Limited normal tissue studies, using both early 
and late responding endpoints, suggest no enhancement of 
radiation damage, thus a therapeutic benefit is observed. In 
this review we will briefly discuss the development of VDAs 
and the current status of both pre-clinical and clinical 
studies. 
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Purpose: In proton therapy, anatomical changes may cause 
considerable deterioration of the delivered dose 
distributions. Transmission-based treatment verification is 
generally not possible, making three-dimensional (3D) 
dosimetry a promising tool for verification of the delivered 
dose. However, solid state 3D detectors have shown 
significant problems related to linear-energy-transfer 
dependent quenching in particle beams – an under-response 
of the signal in the Bragg peak. A new deformable, silicone-
based, radiochromic 3D dosimeter has recently been 
developed by our group. The aim of this study was to perform 
the first proton beam experiments with this detector. Special 
attention was given to the quenching and dose-rate 
dependencies in general, relating these effects to the 
chemical composition of the dosimeter.  
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Material/methods: Dosimeters (1 x 1 x 4.5 cm3) of varying 
chemical compositions were produced. They contained leuco-
malachite green (LMG) dye as the active component, 
chloroform and silicone elastomer.  
Twelve different batches were irradiated with 60 MeV proton 
beams, using a 40 mm circular collimator, to different doses 
(0 – 30 Gy). Irradiations were performed with both a low and 
a high dose rate (0.23 and 0.55 Gy/s). For comparison, 
depth–dose distributions were measured in water with a 
Markus-type, plane-parallel ionization chamber. 
Simultaneously, dosimeters from the same batches were 
irradiated with 6 MV photon beams in a 10 cm square field on 
a linear accelerator. 
All dosimeters were read out before irradiation and four 
hours after, at a wavelength of 635 nm. The read-out was 
performed with a home-built 1D-scanner with a depth 
resolution of 0.2 mm for the proton irradiated dosimeters, 
while a spectrophotometer was used for the photon read-out. 
The dose-rate dependency was compared for proton and 
photon irradiations. The ratio of Bragg-peak to plateau 
response (at 1 cm) was compared between batches. 
Results: The effect of lowering the dose rate was similar for 
proton and photon beams, although the beam qualities were 
different. The dose response was higher at a low dose rate, 
but at increasing dye concentration the effect was reduced. 
Significant under-response was observed in the Bragg peak. 
The peak-to-plateau ratio was improved from (2.5 ± 0.1) to 
(3.0 ± 0.04) by increasing the dye concentration from 0.1 to 
0.3 % (w/w). By increasing the curing-agent concentration 
from 5 to 9 % (w/w), the ratio further improved to (3.7 ± 0.4) 
and (3.5 ± 0.1) for the same respective dye concentrations.  
Conclusion: The 3D radiochromic silicone based dosimeter 
has for the first time been investigated in proton beams, and 
it was demonstrated that chemical modifications could 
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Purpose: There is interest in the particle therapy community 
to use prompt gammas (PG), a natural byproduct of particle 
treatment, for range verification and eventually dose control 
(Knopf et al. 2015). However, PG production is a rare process 
and therefore estimating PGs exiting a patient during a 
proton treatment plan executed by a Monte-Carlo simulation 
converges slowly. Recently, different approaches to 
accelerating the estimation of PG yield have been presented. 
Sterpin et al. (2015) described an analytic method that is 
about to be implemented in a commercial product, but has 
as drawback sensitivity to heterogeneities. Kanawati et al. 
(2015) described a variance reduction method (pgTLE) that 
accelerates the PG estimation by precomputing PG 
production probabilities as a function of energy and target 
materials, but has as drawback that it only works for 
analytical phantoms. 
Materials/Methods: We present a two-stage method, 
voxellized pgTLE (vpgTLE) that extends pgTLE to voxellized 
volumes. PG production probabilities are precomputed once, 
stored, and reused. In stage one, we simulate the 
interactions between the treatment plan and the patient CT 
with low statistic MC to obtain the spatial and spectral 
distribution of the PGs. As primary particles are propagated 
throughout the patient CT, the PG yields are computed in 
each voxel from the initial database, as function of the 
current energy of the primary, the material in the voxel and 
the step length. The result is a voxellized PG yield image, 
normalized to a single primary. The second stage uses the 
intermediate PG image as a source to generate and 
propagate PGs throughout the rest of the scene geometry, 
e.g. into a detection device, proportional to the number of 
primaries desired. 
Results: We have achieved a global speed-up of around 103 
for a heterogeneous phantom, for a 2% relative uncertainty 
on the PG yield. The method agrees with a reference Monte 
Carlo simulation to within 1% at the level of 2% relative 
uncertainty on the PG. Preliminary work on a full simulation 
of a clinical spot-scanning treatment plan and a patient CT 
image indicates a similar gain factor. Gains per voxel range 
from 102 to 105. 
Conclusion: We presented a generic PG yield estimator, drop-
in usable with any geometry and beam configuration. We 
showed a gain of around three orders of magnitude compared 
to analog MC. With a large number of voxels and materials, 
memory consumption may be a concern and we will discuss 
the consequence and possible trade-offs. The method will be 
available in the next release of Gate. 
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Metabolic Tumour Volume (MTV) is defined as the volume on 
FDG-PET/CT with increased FDG uptake. MTV has been shown 
to be of superior prognostic value compared to SUVmax in 
NSCLC. This study aims to explore the spatial overlap 
between CT-derived Gross Tumour Volume (GTV) and FDG-
PET/CT derived MTV. The second aim was to investigate the 
impact of this overlap on progression-free survival (PFS) and 
overall survival (OS). 
This was a single institution review performed in South 
Western Sydney, Australia. Inclusion criteria included proven 
NSCLC, stage I-III disease, radical radiotherapy and received 
PET imaging no more than 105 days before Tx. All FDG-PET 
